# US 2009/0221571 A1 · Hiv integrase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221571 A1
- Document ID: US20090221571A1
- Status: Published application
- Kind: A1
- Application number: 11/992,531
- Filed: 2006-09-26
- Published: 2009-09-03
- Earliest claimed: 2006-09-26
- Assignees: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
- Inventors: Vincenzo Summa; Olaf Kinzel; Monica Donghi
- Web page: https://patentgrep.com/patent/US20090221571A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pyridopyrimidine carboxamide compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein R1, R2, R3, R4, R5 and R6 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

## Claims

### Claim 1

A compound of Formula I, or a pharmaceutically acceptable salt thereof:
wherein
R1, R2, R3, and R4 are each independently:
(1) RA,
(2) RE,
(3) C(O)RA,
(4) C(O)RE,
(5) C(O)ORA,
(6) C(O)ORE,
(7) C(O)N(RA)RB,
(8) C(O)N(RA)RE,
(9) OC(O)RA,
(10) OC(O)RE,
(11) OC(O)N(RA)RB,
(12) OC(O)N(RA)RE,
(13) N(RA)RB,
(14) N(RA)RE,
(15) N(RA)C(O)RB,
(16) N(RA)C(O)RE,
(17) N(RA)C(O)ORB,
(18) N(RA)C(O)ORE,
(19) N(RA)C(O)N(RA)RB,
(20) N(RA)C(O)N(RA)RE,
(21) N(RA)C(O)C(O)N(RA)RB,
(22) N(RA)C(O)C(O)N(RA)RE,
(23) N(RA)S(O)2RB,
(24) N(RA)S(O)2RE,
(25) N(RA)S(O)2N(RA)RB,
(26) N(RA)S(O)2N(RA)RE,
(27) ORA,
(28) ORE,
(29) SRA, S(O)RA, or S(O)2RA,
(30) SRE, S(O)RE, or S(O)2RE,
(31) S(O)2N(RA)RB,
(32) S(O)2N(RA)RE,
(33) CycA, AryA, HetA, or HetR,
(34) C1-6 alkyl substituted with CycA, AryA, HetA, or HetR,
(35) J-CycA, J-AryA, J-HetA, or J-HetR,
(36) C1-6 alkylene-J-CycA, C1-6 alkylene-J-AryA, C1-6 alkylene-J-HetA, or C1-6 alkylene-J-HetR,
(37) J-C1-6 alkylene-CycA, J-C1-6 alkylene-AryA, J-C1-6 alkylene-HetA, or J-C1-6 alkylene-HetR,
(38) C1-6 alkylene-J-C1-6 alkylene-CycA, C1-6 alkylene-J-C1-6 alkylene-AryA, C1-6 alkylene-J-C1-6 alkylene-HetA, or C1-6 alkylene-J-C1-6 alkylene-HetR, or
(39) halogen;
with the proviso that no more than one of R1, R2, R3, and R4 is other than RA, RE, or C1-6 alkyl substituted with CycA, AryA, HetA, or HetR;
R5 is RA, RE, or RF;
R6 is C1-6 alkyl substituted with CycB, AryB, HetB, or HetS;
J is:
(1) O,
(2) S,
(3) S(O),
(4) S(O)2,
(5) C(O),
(6) C(O)O,
(7) C(O)N(RA),
(8) C(O)N(RF),
(9) N(RA),
(10) N(RF),
(11) N(RA)C(O),
(12) N(RF)C(O),
(13) N(RA)C(O)C(O),
(14) N(RF)C(O)C(O),
(15) N(RA)C(O)O,
(16) N(RF)C(O)O
(17) N(RA)S(O)2, or
(18) N(RF)S(O)2;
each RA is independently H or C1-6 alkyl;
each RB is independently H or C1-6 alkyl;
each RE is independently C1-6 haloalkyl or C1-6 alkyl substituted with OH, O—C1-6 alkyl, O—C1-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)—O—C1-6 alkyl, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)RA, OC(O)N(RA)RB, or N(RA)C(O)N(RA)RB;
each RF is independently C1-6 alkyl substituted with CycA, AryA, HetA, or HetR;
each CycA is independently C3-8 cycloalkyl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
(i) from zero to 6 substituents are each independently:
(1) halogen,
(2) CN
(3) C1-6 alkyl,
(4) OH,
(5) O—C1-6 alkyl,
(6) C1-6 haloalkyl, or
(7) O—C1-6 haloalkyl, and
(ii) from zero to 2 substituents are each independently:
(1) CycE,
(2) AryE,
(3) O-AryE,
(4) HetE,
(5) HetF, or
(6) C1-6 alkyl substituted with CycE, AryE, O-AryE, HetE, O-HetE, or HetF;
each AryA is independently aryl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
(i) from zero to 6 substituents are each independently:
(1) C1-6 alkyl,
(2) C1-6 alkyl substituted with OH, O—C1-6 alkyl, O—C1-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)RA, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, or N(RA)C(O)C(O)N(RA)RB,
(3) O—C1-6 alkyl,
(4) C1-6 haloalkyl,
(5) O—C1-6 haloalkyl,
(6) OH,
(7) halogen,
(8) CN,
(9) NO2,
(10) N(RA)RB,
(11) C(O)N(RA)RB,
(12) C(O)RA,
(13) C(O)—C1-6haloalkyl,
(14) C(O)ORA,
(15) OC(O)RA,
(16) OC(O)N(RA)RB,
(17) SRA,
(18) S(O)RA,
(19) S(O)2RA,
(20) S(O)2N(RA)RB,
(21) N(RA)S(O)2RB,
(22) N(RA)S(O)2N(RA)RB,
(23) N(RA)C(O)RB,
(24) N(RA)C(O)N(RA)RB,
(25) N(RA)C(O)—C(O)N(RA)RB, or
(26) N(RA)CO2RB, and
(ii) from zero to 2 substituents are each independently:
(1) CycE,
(2) O-CycE
(3) AryE,
(4) O-AryE,
(5) HetE,
(6) O-HetE,
(7) HetF,
(8) O-HetF or
(9) C1-6 alkyl substituted with CycE, O-CycE, AryE, O-AryE, HetE, O-HetE, O-HetF, or HetF;
each HetA is independently heteroaryl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
(i) from zero to 6 substituents are each independently:
(1) C1-6 alkyl,
(2) C1-6 alkyl substituted with OH, O—C1-6 alkyl, O—C1-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)RA, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, or N(RA)C(O)C(O)N(RA)RB,
(3) O—C1-6 alkyl,
(4) C1-6 haloalkyl,
(5) O—C1-6 haloalkyl,
(6) OH,
(7) oxo,
(8) halogen,
(9) CN,
(10) NO2,
(11) N(RA)RB,
(12) C(O)N(RA)RB,
(13) C(O)RA,
(14) C(O)—C1-6 haloalkyl,
(15) C(O)ORA,
(16) OC(O)RA,
(17) OC(O)N(RA)RB,
(18) SRA,
(19) S(O)RA,
(20) S(O)2RA,
(21) S(O)2N(RA)RB,
(22) N(RA)S(O)2RB,
(23) N(RA)S(O)2N(RA)RB,
(24) N(RA)C(O)RB,
(25) N(RA)C(O)N(RA)RB,
(26) N(RA)C(O)—C(O)N(RA)RB, or
(27) N(RA)CO2RB, and
(ii) from zero to 2 substituents are each independently:
(1) CycE,
(2) O-CycE
(3) AryE,
(4) O-AryE,
(5) HetE,
(6) O-HetE,
(7) HetF,
(8) O-HetF or
(9) C1-6 alkyl substituted with CycE, O-CycE, AryE, O-AryE, HetE, O-HetE, O-HetF, or HetF;
each HetR is independently (i) a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2 or (ii) a 6- to 10-membered saturated or mono-unsaturated, bridged or fused heterobicyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2; and wherein the saturated or mono-unsaturated heterocyclic or heterobicyclic ring is optionally substituted with a total of from 1 to 4 substituents, wherein:
(i) from zero to 4 substituents are each independently halogen, CN, C1-6 alkyl, OH, oxo, C(O)RA, CO2RA, S(O)RA, SRA, S(O)2RA, O—C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylene-CN, C1-6 alkylene-OH, or C1-6 alkylene-O—C1-6 alkyl; and
(ii) from zero to 2 substituents are each independently CycE, O-CycE, AryE, O-AryE, HetE, O-HetE, HetF, O-HetF, or C1-6 alkyl substituted with CycE, O-CycE, AryE, O-AryE, HetE, O-HetE, HetF, O-HetF;
CycB independently has the same definition as CycA;
AryB independently has the same definition as AryA;
HetB independently has the same definition as HetA;
HetS independently has the same definition as HetR;
each aryl is independently (i) phenyl, (ii) a 9- or 10-membered bicyclic, fused carbocylic ring system in which at least one ring is aromatic, or (iii) an 11- to 14-membered tricyclic, fused carbocyclic ring system in which at least one ring is aromatic;
each heteroaryl is independently (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered bicyclic, fused ring system containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein either one or both of the rings contain one or more of the heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2;
each CycE is independently C3-8 cycloalkyl which is optionally substituted with a total of from 1 to 4 substituents, wherein:
(i) from zero to 4 substituents are each independently halogen, C1-6 alkyl, OH, O—C1-6 alkyl, C1-6 haloalkyl, or O—C1-6 haloalkyl, and
(ii) from zero to 2 substituents are each independently CycG, AryG, HetG, HetH, or C1-6 alkyl substituted with CycG, AryG, O-AryG, HetG, or HetH;
each AryE is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with a total of from 1 to 5 substituents, wherein:
(i) from zero to 5 substituents are each independently halogen, CN, NO2, C1-6 alkyl, C1-6 haloalkyl, OH, O—C1-6 alkyl, O—C1-6 haloalkyl, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, SO2RA, SO2N(RA)RB, or SO2N(RA)C(O)RB, and
(ii) from zero to 2 substituents are each independently CycG, AryG, HetG, HetH, or C1-6 alkyl substituted with CycG, AryG, O-AryG, HetG, or HetH;
each HetE is independently (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered fused heterobicyclic ring selected from 2,3-dihydrobenzo-1,4-dioxinyl and benzo-1,3-dioxolyl; and wherein the heteroaromatic ring or the heterobicyclic ring is optionally substituted with a total of from 1 to 4 substituents wherein:
(i) from zero to 4 substituents are each independently halogen, C1-6 alkyl, C1-6 haloalkyl, O—C1-6 alkyl, O—C1-6 haloalkyl, OH, C(O)RA, CO2RA, SO2RA, N(RA)RB, N(RA)C(O)N(RA)RB, or N(RA)CO2RB, and
(ii) from zero to 2 substituents are each independently CycG, AryG, HetG, HetH, or C1-6 alkyl substituted with CycG, AryG, O-AryG, HetG, or HetH;
each HetF is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono-unsaturated heterocyclic ring is optionally substituted with a total of from 1 to 4 substituents, wherein:
(i) from zero to 4 substituents are each independently halogen, CN, C1-6 alkyl, OH, oxo, O—C1-6 alkyl, C1-6 haloalkyl, O—C1-6 haloalkyl, C(O)RA, CO2RA, or SO2RA, and
(ii) from zero to 2 substituents are each independently CycG, AryG, HetG, HetH, or C1-6 alkyl substituted with CycG, AryG, O-AryG, HetG, or HetH;
each CycG is independently C3-8 cycloalkyl which is optionally substituted with from 1 to 4 substituents, each of which is independently halogen, C1-6 alkyl, OH, O—C1-6 alkyl, C1-6 haloalkyl, or O—C1-6 haloalkyl;
each AryG is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents each of which is independently halogen, CN, NO2, C1-6 alkyl, C1-6 haloalkyl, OH, O—C1-6 alkyl, O—C1-6 haloalkyl, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, SO2RA, SO2N(RA)RB, or SO2N(RA)C(O)RB; each HetG is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, C1-6 alkyl, C1-6 haloalkyl, O—C1-6 alkyl, O—C1-6 haloalkyl, OH, C(O)RA, CO2RA, SO2RA, N(RA)RB, N(RA)C(O)N(RA)RB, or N(RA)CO2RB; and
each HetH is independently a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S(O) or S(O)2, and wherein the saturated or mono-unsaturated heterocyclic ring is optionally substituted with from 1 to 4 substituents, each of which is independently halogen, CN, C1-6 alkyl, OH, oxo, O—C1-6 alkyl, C1-6 haloalkyl, O—C1-6 haloalkyl, C(O)RA, CO2RA, or SO2RA.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is as defined in claim 1 and R2, R3, and R4 are each RA; or R3 is as defined in claim 1 and R1, R2, and R4 are each RA.

### Claim 3 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein one of R1, R2, R3, and R4 is:
(1) H,
(2) C1-6 alkyl,
(3) C1-6 alkyl substituted with N(RA)RB or N(RA)O—C1-6 alkyl,
(4) N(RA)RB,
(5) N(RA)C(O)—C1-6 alkyl, wherein the alkyl is optionally substituted with N(RA)RB or S(O)2RA,
(6) N(RA)C(O)C(O)N(RA)RB,
(7) AryA,
(8) HetR,
(9) C1-6 alkyl substituted with HetR,
(10) N(RA)C(O)C(O)-HetR,
(11) N(RA)C(O)-AryA,
(12) N(RA)C(O)-HetA,
(13) N(RA)C(O)-HetR,
(14) N(RA)C(O)—C1-6 alkylene-AryA,
(15) N(RA)C(O)—C1-6 alkylene-HetA,
(16) N(RA)C(O)—C1-6 alkylene-HetR,
(17) C1-6 alkylene-N(RA)C(O)-AryA,
(18) C1-6 alkylene-N(RA)C(O)-HetA,
(19) N(RA)C(O)O—C1-6 alkylene-AryA,
(20) N(RA)C(O)O—C1-6 alkylene-HetA,
(21) O—C1-6 alkylene-AryA,
(22) O—C1-6 alkylene-HetA, or
(23) halogen;
the other three of R1, R2, R3, and R4 are each independently H or C1-6 alkyl.

### Claim 4 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R5 is RA.

### Claim 5 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R5 is H.

### Claim 6 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is CH2-AryB.

### Claim 7 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is:
the asterisk * denotes the point of attachment of R6 to the rest of the compound; X1 and X2 are each independently:
(1) H,
(2) C1-6 alkyl,
(3) OH
(4) O—C1-6 alkyl,
(5) C1-6 haloalkyl,
(6) O—C1-6 haloalkyl,
(7) halogen,
(8) CN,
(9) N(RA)RB,
(10) C(O)N(RA)RB,
(11) SRA,
(12) S(O)RA,
(13) SO2RA,
(14) N(RA)SO2RB,
(15) N(RA)SO2N(RA)RB,
(16) N(RA)C(O)RB,
(17) N(RA)C(O)C(O)N(RA)RB, or
(18) HetE;
or alternatively X1 and X2 are respectively located on adjacent carbons in the phenyl ring and together form methylenedioxy or ethylenedioxy; and
X3 is:
(1) H,
(2) C1-6 alkyl,
(3) O—C1-6 alkyl,
(4) C1-6 haloalkyl,
(5) O—C1-6 haloalkyl, or
(6) halogen.

### Claim 8 (depends on 7)

The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein X1 and X2 in the definition of R6 are each independently: (1) H, (2) C1-4 alkyl, (3) C1-4 haloalkyl, (4) OH, (5) O—C1-4 alkyl, (6) halogen, (7) CN, (8) C(═O)NH2, (9) C(═O)NH(—C1-4 alkyl), (10) C(═O)N(—C1-4 alkyl)2, or (11) SO2-C1-4 alkyl; or alternatively X1 and X2 are respectively located on adjacent carbons in the phenyl ring and together form methylenedioxy or ethylenedioxy; and X3 is H, halogen, C1-4 alkyl, or O—C1-4 alkyl.

### Claim 9 (depends on 8)

The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R6 is:
the asterisk * denotes the point of attachment of R1 to the rest of the compound;
X1 is H, bromo, chloro, fluoro, or methoxy; and
X2 is H, bromo, chloro, fluoro, methoxy, C1-4 alkyl, CF3, OCF3, CN, or SO2(C1-4 alkyl).

### Claim 10 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is CH2-AryB; and AryB is 4-fluorophenyl or 3-chloro-4-fluorophenyl.

### Claim 11 (depends on 10)

The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein AryB is 4-fluorophenyl.

### Claim 12 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is:
(1) H,
(2) C1-6 alkyl,
(3) C1-6 alkyl substituted with N(RA)RB or N(RA)O—C1-6 alkyl,
(4) N(RA)RB,
(5) N(RA)C(O)—C1-6 alkyl, wherein the alkyl is optionally substituted with N(RA)RB or S(O)2RA,
(6) N(RA)C(O)C(O)N(RA)RB,
(7) HetR,
(8) C1-6 alkyl substituted with HetR,
(9) N(RA)C(O)C(O)-HetR,
(10) N(RA)C(O)-AryA,
(11) N(RA)C(O)-HetA,
(12) N(RA)C(O)-HetR,
(13) N(RA)C(O)—C1-6 alkylene-AryA,
(14) N(RA)C(O)—C1-6 alkylene-HetA,
(15) N(RA)C(O)—C1-6 alkylene-HetR,
(16) C1-6 alkylene-N(RA)C(O)-AryA,
(17) C1-6 alkylene-N(RA)C(O)-HetA,
(18) N(RA)C(O)O—C1-6 aLkylene-AryA,
(19) N(RA)C(O)O—C1-6 alkylene-HetA,
(20) O—C1-6 alkylene-AryA, or
(21) O—C1-6 alkylene-HetA;
R2, R3, and R4 are each independently H or C1-6 alkyl;
R5 is H or C1-6 alkyl; and
R6 is CH2-AryB.

### Claim 13 (depends on 12)

The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein:
R1 is:
(1) H,
(2) C1-4 alkyl,
(3) C1-4 alkyl substituted with N(RA)RB or N(RA)O—C1-4 alkyl,
(4) N(RA)RB,
(5) N(RA)C(O)—C1-4 alkyl,
(6) N(RA)C(O)—(CH2)1-2N(RA)RB,
(7) N(RA)C(O)—(CH2)1-2S(O)2RA,
(8) N(RA)C(O)C(O)N(RA)RB,
(9) HetR,
(10) (CH2)1-2-HetR,
(11) N(RA)C(O)C(O)-HetR,
(12) N(RA)C(O)-AryA,
(13) N(RA)C(O)-HetA,
(14) N(RA)C(O)-HetR,
(15) N(RA)C(O)—(CH2)1-2-AryA,
(16) N(RA)C(O)—(CH2)1-2-HetA,
(17) N(RA)C(O)—(CH2)1-2-HetR,
(18) (CH2)1-2—N(RA)C(O)-AryA,
(19) (CH2)1-2—N(RA)C(O)-HetA,
(20) N(RA)C(O)O—(CH2)1-2-AryA,
(21) N(RA)C(O)O—(CH2)1-2-HetA,
(22) O—(CH2)1-2-AryA, or
(23) O—(CH2)1-2-HetA,
R2, R3, and R4 are each independently H or C1-4 alkyl;
R5 is H or C1-4 alkyl;
R6 is CH2-AryB;
each RA is independently H or C1-4 alkyl;
each RB is independently H or C1-4 alkyl;
AryA is phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with a total of from 1 to 5 substituents, wherein:
(i) from zero to 5 substituents are each independently:
(1) C1-4 alkyl,
(2) O—C1-4 alkyl,
(3) C1-4 haloalkyl,
(4) O—C1-4 haloalkyl,
(5) OH,
(6) halogen,
(7) CN,
(8) NO2,
(9) N(RA)RB,
(10) C(O)N(RA)RB,
(11) C(O)—C1-4alkyl,
(12) CO2—C1-4 alkyl,
(13) S—C1-4 alkyl,
(14) S(O)—C1-4 alkyl,
(15) SO2—C1-4 alkyl,
(16) SO2N(RA)RB,
(17) SO2N(RA)C(O)—C1-4 alkyl, or
(18) N(RA)C(O)—C1-4 alkyl, and
(ii) from zero to 1 substituent is AryE, HetE, CH2-AryE, or CH2-HetE;
HetA is (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered bicyclic, fused ring system containing a total of from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero to 20 atoms, and zero to 2 S atoms, wherein either one or both of the rings contain one or more of the heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2; wherein the heteroaromatic ring or the bicyclic, fused ring system is optionally substituted with a total of from 1 to 4 substituents, wherein:
(i) from zero to 4 substituents are each independently:
(1) C1-4 alkyl,
(2) O—C1-4 alkyl,
(3) C1-4 haloalkyl,
(4) O—C1-4 haloalkyl,
(5) OH,
(6) Cl, Br, or F,
(7) CN,
(8) C(O)N(RA)RB,
(9) S(O)2—C1-4 alkyl, or
(10) S(O)2N(RA)RB, and
(ii) from zero to 1 substituent is AryE, HetE, CH2-AryE, or CH2-HetE;
HetR is a 4- to 7-membered, saturated or mono-unsaturated heterocyclic ring or a 6- to 10-membered saturated or mono-unsaturated, bridged or fused heterobicyclic ring, wherein the heterocyclic or heterobicyclic ring contains a nitrogen atom which is directly attached to the rest of the molecule and optionally contains an additional heteroatom selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2; and wherein the heterocyclic or heterobicyclic ring is optionally substituted with a total of from 1 to 4 substituents, wherein:
(i) from zero to 4 substituents are each independently Cl, Br, F, C1-4 alkyl, OH, oxo, C(O)—C1-4 alkyl, S(O)2—C1-4 alkyl, O—C1-4 alkyl, O—C1-4 haloalkyl, or C1-4 haloalkyl; and
(ii) from zero to 1 substituent is AryE, HetE, CH2-AryE, or CH2-HetE;
AryB is phenyl which is optionally substituted with from 1 to 5 substituents wherein:
(i) from zero to 5 substituents are each independently:
(1) C1-4alkyl,
(2) OH
(3) O—C1-4 alkyl,
(4) C1-4 haloalkyl,
(5) O—C1-4 haloalkyl,
(6) halogen,
(7) CN,
(8) N(RA)RB,
(9) C(O)N(RA)RB,
(10) SRA,
(11) S(O)RA,
(12) SO2RA,
(13) N(RA)SO2RB,
(14) N(RA)SO2N(RA)RB,
(15) N(RA)C(O)RB, or
(16) N(RA)C(O)C(O)N(RA)RB, and
(ii) from zero to 1 substituent is AryE, HetE, CH2-AryE, or CH2-HetE;
AryE is phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently C1-4 alkyl, O—C1-4 alkyl, C1-4 fluoroalkyl, O—C1-4 fluoroalkyl, Cl, Br, F, CN, C(O)N(RA)RB, S(O)2—C1-4 alkyl, or S(O)2N(RA)RB; and
HetE is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, CN, NO2, C1-4 alkyl, C1-4 fluoroalkyl, OH, O—C1-4 alkyl, or O—C1-4 fluoroalkyl.

### Claim 14 (depends on 13)

The compound according to claim 13, or a pharmaceutically acceptable salt thereof, which is a compound of Formula II:
wherein:
R1 is:
(1) H,
(2) C1-4 alkyl,
(3) CH2N(C1-4 alkyl)2,
(4) CH2N(C1-4 alkyl)—O—C1-4 alkyl,
(5) N(C1-4 alkyl)2,
(6) N(C1-4 alkyl)C(O)—C1-4 alkyl,
(7) N(C1-4 alkyl)C(O)CH2N(C1-4 alkyl)2,
(8) N(C1-4 alkyl)C(O)CH2S(O)2—C1-4 alkyl,
(9) N(C1-4 alkyl)C(O)C(O)(C1-4 alkyl)2,
(10) HetR,
(11) CH2-HetR,
(12) N(C1-4 alkyl)C(O)C(O)-HetR,
(13) N(H)C(O)-AryA,
(14) N(C1-4 alkyl)C(O)-AryA,
(15) N(H)C(O)-HetA,
(16) N(C1-4 alkyl)C(O)-HetA,
(17) N(H)C(O)-HetR,
(18) N(C1-4 alkyl)C(O)-HetR,
(19) N(H)C(O)—(CH2)1-2-AryA,
(20) N(C1-4 alkyl)C(O)—(CH2)1-2-AryA,
(21) N(H)C(O)—(CH2)1-2-HetA,
(22) N(C1-4 alkyl)C(O)—(CH2)1-2-HetA,
(23) N(C1-4 alkyl)C(O)CH2-HetR,
(24) CH2N(H)C(O)-AryA,
(25) CH2N(C1-4 alkyl)C(O)-AryA,
(26) CH2N(H)C(O)-HetA,
(27) CH2N(C1-4 alkyl)C(O)-HetA,
(28) N(H)C(O)OCH2-AryA,
(29) N(C1-4 alkyl)C(O)OCH2-AryA,
(30) N(H)C(O)OCH2-HetA,
(31) N(C1-4 alkyl)C(O)OCH2-HetA,
(32) OCH2-AryA, or
(33) OCH2-HetA;
AryA is phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently bromo chloro, fluoro, methoxy, C1-4 alkyl, CF3, OCF3, CN, or SO2(C1-4 alkyl);
HetA is a heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, and oxadiazolyl, wherein the heteroaromatic ring is optionally substituted with from 1 to 2 substituents each of which is independently a C1-4 alkyl; and
HetR is a heterocyclic ring selected from the group consisting of:
wherein the asterisk denotes the point of attachment of the heterocyclic ring to the rest of the molecule;
X1 is H, bromo, chloro, fluoro, or methoxy; and
X2 is H, bromo, chloro, fluoro, methoxy, C1-4 alkyl, CF3, OCF3, CN, or SO2(C1-4 alkyl).

### Claim 15 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R3 is:
(1) halogen,
(2) AryA, or
(3) HetA;
R1, R2, and R4 are each independently H or C1-6 alkyl;
R5 is H or C1-6 alkyl; and
R6 is CH2-AryB.

### Claim 16 (depends on 15)

The compound according to claim 15, or a pharmaceutically acceptable salt thereof, which is a compound of Formula III:
wherein:
R3 is:
(1) bromine,
(2) AryA, or
(3) HetA;
AryA is phenyl which is optionally substituted with a total of from 1 to 3 substituents, wherein:
(i) from zero to 3 substituents are each independently bromo chloro, fluoro, methoxy, C1-4 alkyl, CF3, OCF3, CN, SO2(C1-4 alkyl), or N(C1-4 alkyl)2, and
(ii) from zero to 1 substituent is:
wherein the asterisk denotes the point of attachment of the heterocyclic ring to the rest of the molecule;
HetA is a heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, and oxadiazolyl, wherein the heteroaromatic ring is optionally substituted with from 1 to 2 substituents each of which is independently a C1-4 alkyl;
X1 is H, bromo, chloro, fluoro, or methoxy; and
X2 is H, bromo, chloro, fluoro, methoxy, C1-4 alkyl, CF3, OCF3, CN, or SO2(C1-4 alkyl).

### Claim 17

A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9-{methyl[(methylsulfonyl)acetyl]amino}-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9-[(N,N,N′-triethyl)-ethanediamide]-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9-(benzyloxy)-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-7-(2-morpholin-4-ylphenyl)-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[acetyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[benzoyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
9-[methylamino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
9-[dimethylamino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[ethylamino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidin-9-yl)-N,N′,N′-trimethylethanediamide;
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidin-9-yl)-N-ethyl-N′,N′-dimethylethanediamide;
benzyl (2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidin-9-yl)carbamate;
9-[benzoylamino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[ethyl(isonicotinoyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[ethyl(pyridin-2-ylcarbonyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidin-9-yl)-N-propyl-N′,N′-dimethylethanediamide;
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidin-9-yl)-N-isobutyl-N′,N′-dimethylethanediamide;
N-(4-fluorobenzyl)-3-hydroxy-9-{ethyl[morpholin-4-yl(oxo)acetyl]amino}-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[(N,N-dimethylglycyl)(ethyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[(N,N-diethylglycyl)(ethyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[ethyl(morpholin-4-ylacetyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-{ethyl[(4-methylpiperazin-1-yl)acetyl]amino}-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
9-[ethyl(1,3-thiazol-4-ylcarbonyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[ethyl(isoxazol-5-ylcarbonyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-{ethyl [(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
9-{ethyl[oxo(pyrrolidin-1-yl)acetyl]amino}-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
4-[[ethyl(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidin-9-yl)amino](oxo)acetyl]-1-methylpiperazine;
N-(4-fluorobenzyl)-3-hydroxy-9-methyl-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
9-[(dimethylamino)methyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido [1,2-α]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9-{[methoxy(methyl)amino]methyl}-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9-(morpholin-4-ylmethyl)-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[(4-acetylpiperazin-1-yl)methyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide;
9-[(benzoylamino)methyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide; and
7-bromo-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4H-pyrido[1,2-α]pyrimidine-2-carboxamide.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A pharmaceutical combination which is (i) a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and (ii) an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, nucleoside HIV reverse transcriptase inhibitors, and non-nucleoside HIV reverse transcriptase inhibitors; wherein the compound of (i) or its pharmaceutically acceptable salt and the HIV infection/AIDS antiviral agent of (ii) are each employed in an amount that renders the combination effective for the treatment of HIV infection or the treatment or delay in the onset of AIDS.

### Claim 20 (depends on 1)

A method for the treatment of HIV infection, or the treatment or delay in the onset of AIDS, wherein the method comprises administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1.

### Claim 21

(canceled)

### Claim 22

(canceled)
